Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kristina Landes"'
Autor:
Matthew Cannon, Hannah Phillips, Sidney Smith, Shaneice Mitchell, Kristina Landes, Payal Desai, John Byrd, Rosa Lapalombella
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2021)
Abstract The in vitro erythrocyte differentiation model remains a strong, clinically relevant tool to model erythroid development in normal and disease related hematopoiesis. This model also has application to developing therapeutics for diseases rel
Externí odkaz:
https://doaj.org/article/e9a5b632336444798af0f7cb1f670131
Autor:
Mitchell Weigand, Jenifer Gomez-Pastora, Jacob Strayer, Xian Wu, Hyeon Choe, Shuwei Lu, Eric Plencner, Kristina Landes, Andre Palmer, Maciej Zborowski, Payal Desai, Jeffrey Chalmers
Publikováno v:
IEEE Transactions on Biomedical Engineering. 69:3582-3590
Sickle cell disease (SCD) is an inherited blood disorder that affects millions of people worldwide, especially in low-resource regions of the world, where a rapid and affordable test to properly diagnose the disease would be highly valued. Magnetopho
Autor:
Vimal K Derebail, Laura Y Zhou, Laila Elsherif, Kammie L Patillo, David Wichlan, Kristina Landes, Paula McCune, Laura R Loehr, Robert M Cronin, Payal C Desai, Jianwen Cai, Kenneth I Ataga
Publikováno v:
Blood. 140:2545-2546
Autor:
Hannah Phillips, Rosa Lapalombella, Shaneice Mitchell, Sidney Smith, Payal Desai, Matthew Cannon, Kristina Landes, John C. Byrd
Publikováno v:
Experimental Hematology & Oncology
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2021)
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2021)
The in vitro erythrocyte differentiation model remains a strong, clinically relevant tool to model erythroid development in normal and disease related hematopoiesis. This model also has application to developing therapeutics for diseases related to r
Autor:
Rosa Lapalombella, Lindsey T. Brinton, Charles Thomas Gregory, Hannah Phillips, Katie Williams, Payal Desai, Matthew Cannon, Kristina Landes, Sidney Smith, John C. Byrd
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 7
Journal of Clinical Medicine, Vol 9, Iss 2276, p 2276 (2020)
Volume 9
Issue 7
Journal of Clinical Medicine, Vol 9, Iss 2276, p 2276 (2020)
Sickle-cell disease (SCD) is a debilitating hematological disorder with very few approved treatment options. Therapeutic reactivation of fetal hemoglobin (HbF) is one of the most pursued methods for ameliorating the systemic manifestations of SCD. De
Autor:
Patrick L. Green, Amanda R. Panfil, Nathan J. Dissinger, Soledad Fernandez, Brandon M. Murphy, Kristina Landes, Cory M Howard
Publikováno v:
Journal of Virology. 90:3760-3772
Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviruses that transform T cells in vitro but have distinct pathological outcomes in vivo . HTLV-1 encodes a protein from the antisense strand of its proviral genom
Publikováno v:
Retrovirology
HTLV-1 and HTLV-2 are highly related retroviruses that transform T-lymphocytes in cell culture, but display distinct pathobiology in vivo. HTLV-1 is the causative infectious agent of adult T-cell leukemia/lymphoma (ATL) and a neurodegenerative diseas
Autor:
Devra Huey, M. Cecilia M. Parrula, Michael Dale Lairmore, Stefan Niewiesk, Kristina Landes, Soledad Fernandez
Adult T cell leukemia/lymphoma (ATL) is a highly aggressive CD4+/CD25+ T-cell malignancy caused by human T cell lymphotropic virus type 1 (HTLV-1). Previous studies in the MET-1 cell/NOD/SCID mouse model of ATL demonstrated that MET-1 cells are very
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c08e37a6e7acdeb7aada7bdf0bc9a2
https://europepmc.org/articles/PMC4134976/
https://europepmc.org/articles/PMC4134976/
Autor:
Bevin Zimmerman, Ching-Shih Chen, Michael Dale Lairmore, Kristina Landes, Soledad Fernandez, Aaron M. Sargeant
Publikováno v:
Leuk Res
Human T-lymphotropic virus type 1 (HTLV-1) causes a variety of forms of adult T-cell leukemia/lymphoma (ATL), a refractory CD4+/CD25+ T-cell malignancy. Novel approaches to treat ATL patients are required due to the resistance of ATL to conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::484bef57ac0162b25142215e48737337
https://europepmc.org/articles/PMC3191315/
https://europepmc.org/articles/PMC3191315/